Empagliflozin (CAS 864070-44-0): A Comprehensive Product Introduction
Empagliflozin, with the CAS number 864070-44-0, is a significant pharmaceutical compound that has gained considerable attention in the medical field. It belongs to a class of drugs known as sodium – glucose co – transporter 2 (SGLT2) inhibitors. These inhibitors play a crucial role in managing blood sugar levels in patients with type 2 diabetes. In this article, we will explore the various aspects of Empagliflozin, including its properties, uses, applications in different fields, and preparation methods.
Properties of Empagliflozin
Empagliflozin has specific physical and chemical properties that make it unique. Chemically, it has a well – defined molecular structure. Its molecular formula is C₂₃H₂₇ClO₇, and it has a molecular weight of approximately 450.91 g/mol. The compound exists as a white to off – white crystalline powder. It has a melting point in a specific range, which is important for its formulation and stability during storage and handling. In terms of solubility, Empagliflozin has limited solubility in water but is soluble in organic solvents such as ethanol and methanol. This solubility profile affects its bioavailability and the way it is formulated into pharmaceutical products.
The compound has certain stability characteristics. It is relatively stable under normal storage conditions, but it may be affected by factors such as light, heat, and humidity. Therefore, proper storage conditions, such as storing in a cool, dry place away from direct sunlight, are recommended to maintain its quality and efficacy. Empagliflozin also has specific spectral properties, which can be used for its identification and quality control during the manufacturing process. For example, its infrared (IR) spectrum shows characteristic absorption bands corresponding to its functional groups, and its nuclear magnetic resonance (NMR) spectrum provides information about its molecular structure and connectivity.
Uses of Empagliflozin
The primary use of Empagliflozin is in the treatment of type 2 diabetes. As an SGLT2 inhibitor, it works by blocking the reabsorption of glucose in the kidneys. Normally, the kidneys filter glucose from the blood, and most of it is reabsorbed back into the bloodstream. Empagliflozin inhibits the SGLT2 protein, which is responsible for this reabsorption process. As a result, more glucose is excreted in the urine, leading to a reduction in blood glucose levels. This mechanism of action is different from other anti – diabetic drugs, such as metformin or sulfonylureas, which work through different pathways in the body.
In addition to its glucose – lowering effect, Empagliflozin has been shown to have other beneficial effects. Clinical studies have demonstrated that it can reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. It can also lead to weight loss, as the excess glucose excreted in the urine represents an energy loss from the body. Moreover, Empagliflozin may have a positive impact on kidney function. It can slow down the progression of kidney disease in patients with type 2 diabetes, reducing the risk of end – stage renal disease.
Another potential use of Empagliflozin is in the management of heart failure. Recent research has suggested that it can improve heart failure outcomes, regardless of whether the patient has diabetes or not. This is an exciting development, as it expands the therapeutic potential of the drug beyond its traditional use in diabetes treatment. The exact mechanism by which Empagliflozin benefits heart failure patients is still being investigated, but it may involve effects on fluid balance, cardiac metabolism, and inflammation.
Applications in Different Fields
Medical Field: In the medical field, Empagliflozin is mainly used in clinical practice for the treatment of type 2 diabetes. It is often prescribed as an adjunct to diet and exercise to improve glycemic control. It can be used alone or in combination with other anti – diabetic drugs, depending on the patient’s condition and the doctor’s judgment. For example, it may be combined with metformin to achieve better blood sugar control. In the case of patients with type 2 diabetes and high cardiovascular risk, Empagliflozin is recommended as part of a comprehensive treatment plan to reduce the risk of cardiovascular events.
Research Field: In the research field, Empagliflozin is a subject of extensive study. Scientists are exploring its potential mechanisms of action in more detail, looking for new therapeutic applications, and studying its long – term effects. For example, research is being conducted to understand how Empagliflozin affects the gut microbiota, as there is growing evidence that the gut microbiota plays a role in diabetes and other metabolic disorders. Additionally, studies are underway to investigate the use of Empagliflozin in other diseases, such as obesity and non – alcoholic fatty liver disease.
Pharmaceutical Industry: In the pharmaceutical industry, Empagliflozin is used in the production of various pharmaceutical formulations. These formulations need to be carefully designed to ensure proper bioavailability, stability, and patient compliance. For example, it can be formulated into tablets, which are the most common dosage form. The manufacturing process of Empagliflozin tablets involves steps such as granulation, compression, and coating to ensure the quality and efficacy of the final product.
Preparation Methods of Empagliflozin
The preparation of Empagliflozin involves a series of chemical reactions. One of the common synthetic routes starts with the appropriate starting materials, which are usually commercially available or can be synthesized in – house. The first step often involves the formation of the basic carbon – carbon framework of the molecule. This may be achieved through coupling reactions, such as Suzuki – Miyaura coupling or Heck coupling, which are widely used in organic synthesis to form carbon – carbon bonds.
After the formation of the basic framework, functional group manipulations are carried out. For example, hydroxyl groups may be protected and deprotected at appropriate stages to ensure the selectivity of the reactions. The introduction of the chlorine atom in the Empagliflozin molecule is also a crucial step. This can be achieved through chlorination reactions using suitable chlorinating agents, such as thionyl chloride or phosphorus pentachloride. The reaction conditions, including temperature, solvent, and reaction time, need to be carefully controlled to obtain a high yield and purity of the product.
Once the main structure of Empagliflozin is synthesized, purification steps are necessary. These purification steps may include recrystallization, column chromatography, or other separation techniques. Recrystallization is a common method for purifying organic compounds, where the crude product is dissolved in a suitable solvent at an elevated temperature and then allowed to crystallize as the solution cools. Column chromatography can be used to separate impurities based on their different affinities for the stationary phase and the mobile phase. The final purified Empagliflozin product is then characterized using various analytical techniques, such as high – performance liquid chromatography (HPLC), mass spectrometry (MS), and NMR, to ensure its identity, purity, and quality.
Send InquiryReferences
- Author1, Title1, Journal1, Volume1, Pages1
- Author2, Title2, Journal2, Volume2, Pages2
- Author3, Title3, Journal3, Volume3, Pages3